150 related articles for article (PubMed ID: 23360626)
21. Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection.
Vidal-Castiñeira JR; López-Vázquez A; Díaz-Peña R; Alonso-Arias R; Martínez-Borra J; Pérez R; Fernández-Suárez J; Melón S; Prieto J; Rodrigo L; López-Larrea C
J Virol; 2010 Jan; 84(1):475-81. PubMed ID: 19846535
[TBL] [Abstract][Full Text] [Related]
22. Outcomes of Interferon/Ribavirin Therapy in Patients with HCV Defined by Expression of Plasma Soluble Human Leukocyte Antigen-G but Not IL-37.
Ding SX; Ma JB; Hu YR; Hu AR; Shen Q; Gao GS
Med Sci Monit; 2016 Apr; 22():1398-402. PubMed ID: 27112970
[TBL] [Abstract][Full Text] [Related]
23. [Change in Serum Levels of New Hepatic Fibrosis Marker "Mac-2 Binding Protein Glycosylation isomer (M2BPGi)" in Patients with Chronic Hepatitis C during the Treatment of Pegylated Interferon and Ribavirin].
Ishida H; Suetsugu A; Nakamura M; Tauchi R; Nakayama J; Katano Y; Shirakami Y; Furuta N; Ito H; Seishima M
Rinsho Byori; 2015 Aug; 63(8):901-6. PubMed ID: 26638424
[TBL] [Abstract][Full Text] [Related]
24. Polymorphisms of HLA-DM on Treatment Response to Interferon/Ribavirin in Patients with Chronic Hepatitis C Virus Type 1 Infection.
Chen H; Yao Y; Wang Y; Zhou H; Xu T; Liu J; Wang G; Zhang Y; Chen X; Liu Q; Huang P; Yu R
Int J Environ Res Public Health; 2016 Oct; 13(10):. PubMed ID: 27775635
[TBL] [Abstract][Full Text] [Related]
25. Treatment of chronic hepatitis C in haemophilic patients with interferon and ribavirin: a meta-analysis.
Franchini M; Mengoli C; Veneri D; Mazzi R; Lippi G; Cruciani M
J Antimicrob Chemother; 2008 Jun; 61(6):1191-200. PubMed ID: 18356154
[TBL] [Abstract][Full Text] [Related]
26. Clearance and persistence of hepatitis C virus in a Tunisian population: association with HLA class I and class II.
Ksiaa L; Ayed-Jendoubi S; Sfar I; Gorgi Y; Najjar HA; Abdallah TB; Ayed K
Viral Immunol; 2007; 20(2):312-9. PubMed ID: 17603847
[TBL] [Abstract][Full Text] [Related]
27. MicroRNAs as predictor markers for response to interferon treatment of chronic hepatitis C genotype-4 in Egyptian patients.
Motawi TM; Rizk SM; Shaker OG; Mokhtar OZ
PLoS One; 2015; 10(3):e0121524. PubMed ID: 25811198
[TBL] [Abstract][Full Text] [Related]
28. Effect of human leukocyte antigen class I and II alleles on hepatitis C viral load among chronic hepatitis C patients in Southern Taiwan.
Tseng KC; Tseng CW; Hsieh YH; Chang CK; Lai NS; Hung TH; Chang TT
Hum Immunol; 2013 Aug; 74(8):978-82. PubMed ID: 23628398
[TBL] [Abstract][Full Text] [Related]
29. Treatment of chronic hepatitis-C with standard interferon and ribavirin.
Jadoon SA; Jadoon HA; Nazar HS
J Ayub Med Coll Abbottabad; 2014; 26(2):212-5. PubMed ID: 25603680
[TBL] [Abstract][Full Text] [Related]
30. HFE gene mutations prevent sustained virological response to interferon plus ribavirin in chronic hepatitis C patients with serum markers of iron overload.
Coelho-Borges S; Cheinquer H; Cheinquer N; Krug L; Ashton-Prolla P
Am J Gastroenterol; 2002 Jun; 97(6):1570-2. PubMed ID: 12094895
[No Abstract] [Full Text] [Related]
31. Response of TT virus to IFN plus ribavirin treatment in patients with chronic hepatitis C.
Moreno J; Moraleda G; Barcena R; Mateos M; del Campo S
World J Gastroenterol; 2004 Jan; 10(1):143-6. PubMed ID: 14695786
[TBL] [Abstract][Full Text] [Related]
32. Screening for autoantibodies in chronic hepatitis C patients has no effect on treatment initiation or outcome.
Mauss S; Berger F; Schober A; Moog G; Heyne R; John C; Pape S; Hueppe D; Pfeiffer-Vornkahl H; Alshuth U
J Viral Hepat; 2013 Apr; 20(4):e72-7. PubMed ID: 23490392
[TBL] [Abstract][Full Text] [Related]
33. Utility of early testing for HCV viremia as predictive factor of sustained response during interferon or interferon plus ribavirin treatment.
Castro FJ; Esteban JI; Sauleda S; Viladomiu L; Dragon EA; Esteban R; Guardia J
J Hepatol; 2000 May; 32(5):843-9. PubMed ID: 10845673
[TBL] [Abstract][Full Text] [Related]
34. [HLA class II alleles and response to hepatitis C treatment with interferon alpha2b].
Piekarska A; Woszczek G; Sidorkiewicz M; Kuydowicz J
Przegl Epidemiol; 2002; 56(1):123-8. PubMed ID: 12150055
[TBL] [Abstract][Full Text] [Related]
35. Cochrane systematic review: pegylated interferon plus ribavirin vs. interferon plus ribavirin for chronic hepatitis C.
Simin M; Brok J; Stimac D; Gluud C; Gluud LL
Aliment Pharmacol Ther; 2007 May; 25(10):1153-62. PubMed ID: 17451561
[TBL] [Abstract][Full Text] [Related]
36. Nonsynonymous variant Pro70Ser (rs117648444) in IFNL4 gene identifies carriers of the rs368234815 ΔG allele with higher HCV RNA decline during the first 4 weeks of pegylated interferon and ribavirin therapy in HCV-1 patients.
Galmozzi E; Aghemo A
J Clin Virol; 2014 Apr; 59(4):274-5. PubMed ID: 24495847
[No Abstract] [Full Text] [Related]
37. Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy.
Rosen HR; Weston SJ; Im K; Yang H; Burton JR; Erlich H; Klarquist J; Belle SH;
Hepatology; 2007 Aug; 46(2):350-8. PubMed ID: 17659573
[TBL] [Abstract][Full Text] [Related]
38. Extended treatment duration for treatment naïve chronic hepatitis C genotype 1 late viral responders: a meta-analysis comparing 48 weeks vs 72 weeks of pegylated interferon and ribavirin.
Parikh M; Singh A; Sood G
J Viral Hepat; 2011 Apr; 18(4):e99-103. PubMed ID: 20950407
[TBL] [Abstract][Full Text] [Related]
39. Coevolution of the hepatitis C virus polyprotein sites in patients on combined pegylated interferon and ribavirin therapy.
Lara J; Xia G; Purdy M; Khudyakov Y
J Virol; 2011 Apr; 85(7):3649-63. PubMed ID: 21248044
[TBL] [Abstract][Full Text] [Related]
40. Antiviral therapy for chronic hepatitis C in patients with inherited bleeding disorders: an international, multicenter cohort study.
Posthouwer D; Yee TT; Makris M; Fischer K; Griffioen A; Van Veen JJ; Mauser-Bunschoten EP
J Thromb Haemost; 2007 Aug; 5(8):1624-9. PubMed ID: 17663735
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
